TipRanks
Go Ultimate55% OFF

Hemab Therapeutics Holdings, Inc. (COAG) Financial Statements

Hemab Therapeutics Holdings, Inc. Financial Overview

Hemab Therapeutics Holdings, Inc.'s market cap is currently $1.94B. The company's EPS TTM is $-1.31; its P/E ratio is -31.64; Hemab Therapeutics Holdings, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25
Income Statement
Total Revenue$ 0.00
Gross Profit$ 0.00
Operating Income$ -70.12M
EBITDA$ -69.81M
Net Income$ -63.91M
Balance Sheet
Cash & Short-Term Investments$ 185.49M
Total Assets$ 194.78M
Total Debt$ 1.22M
Net Debt$ -86.75M
Total Liabilities$ 371.42M
Stockholders' Equity$ -176.63M
Cash Flow
Free Cash Flow$ -61.49M
Operating Cash Flow$ -61.48M
Investing Cash Flow$ -81.48M
Financing Cash Flow$ 156.30M

Currency in USD

Hemab Therapeutics Holdings, Inc. Earnings and Revenue History

-75M-50M-25M00 %0.4 %0.8 %1.2 %EarningsProfit Margin2025RevenueEarningsProfit Margin

Hemab Therapeutics Holdings, Inc. Debt to Assets

0150M300M450M189 %190 %191 %192 %LiabilitiesDebt to Assets2025AssetsLiabilitiesDebt to Assets

Hemab Therapeutics Holdings, Inc. Cash Flow

-100M-50M050M100M150M200M2025OperatingInvestingFinancing

Hemab Therapeutics Holdings, Inc. Forecast EPS vs Actual EPS

-30-25-20-15-10-505Q1 26Q2 26EPS EstimateBeatMiss